Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz

01-06-2021

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital 12 de Octubre, Luis Álvarez-Vallina, ha explicado el diseño de un nuevo anticuerpo que potencia la respuesta del sistema inmunitario frente a las células tumorales y elimina las reacciones adversas asociadas a los tratamientos convencionales. (Fuente: Madrid Salud)

https://www.abc.es/espana/abci-investigadores-crean-nuevo-anticuerpo-ant...

Leadartis to present on May 26th, 2021 its business to the 17th Annual Anglonordic Life Science Conference

20-05-2021

Anglonordic is a great event to meet quality investors and companies - it is very well run and given the invitation only status it is well attended with quality investors and companies. This year we're excited since we can extend our reach to such a global and expert audience. 

https://www.anglonordiclifescience.com/page/conferenceagenda

Clave Capital invests in Leadartis in a funding round of more than €1,600,000

14-05-2021

Clave Capital, through the fund Navarra Tech Transfer, consolidates with this new operation its commitment in the field of human health, in this case, together with Sodena and Capital Cell.http://capital-riesgo.es/es/articles/clave-invierte-en-leadartis-en-una-ronda-de-financiaci-n-de-m-s-de-1-600-000/

Sodena and Capital Cell invest €1.600.000 in the biopharmaceutical Leadartis

30-04-2021

The entry of funds into leadartis' shareholding is part of a round of financing closed by the company in recent times. "An action that has endowed it with 1.6 million euros that will advance the development of the first immunotherapy candidate against advanced cancers with high medical need such as lung, colon and breast."

Leadartishttps://www.webcapitalriesgo.com/leadartis-cierra-una-ronda-de-e16m-a-la-que-acuden-sodena-y-capital-cell

Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models

13-01-2021

Leadartis reaches a major milestone with the demonstration of absence of toxicity of its EGFR-targeted 4-1BB-agonistic bispecific Trimerbody which does not Induce Hepatotoxicity in transgenic mice with liver expression of human EGFR (https://www.frontiersin.org/articles/10.3389/fimmu.2020.614363/full).

Leadartis closes the investment round in 14 days with an overfunding of 25%

28-09-2020

We are pleased to inform you that the investment round has been successfully closed, raising a total of € 1,250,000 euros, equivalent to 125% of the published goal of 1,000,000 euros. https://capitalcell.es/campaign/leadartis/. We will provide you with additional details as we complete the formalities.

Thank you very much for your participation.

Juan J. Perez Villar, Leadartis CEO

Fund Raising Update: Round completed

21-09-2020

In only ten days Leadartis has completed 100% of its fund-raising needs.

We thank you all for your support! We will allow a small overfunding amount, act quickly if you don´t want to miss out!! Visit the following link should you are still interested in participating. https://capitalcell.es/campaign/leadartis/

Regards, Juan J. Perez Villar, Leadartis CEO

Syndicate content

Latest News

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021

...

Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...

Leadartis to present on May 26th, 2021 its business to the 17th Annual Anglonordic Life Science Conference
20-05-2021

Anglonordic is a great event to meet quality investors and companies - it is very well run and...